Design, in vitro and in vivo evaluation of glipizide Eudragit microparticles.
Glipizide microparticles made with Eudragit (RS 100 and RL 100), prepared by emulsion solvent evaporation technique were evaluated for various in-vitro properties viz. encapsulation efficiency, particle size and surface morphology, drug release pattern and in-vivo hypoglycaemic activity. The optimized formulation parameters were used to prepare smooth and spherical microparticles (2-32 microm) with higher entrapment efficiency (67-89%). Drug release patterns of glipizide microparticles of Eudragit RS 100 and Eudragit RL 100 with drug-to-polymer ratio of 1 : 4 (i.e. EGM14 and ELGM14) have shown gradual and extended release for 24 h with cumulative release of glipizide to the extent of 72.3% and 83.9%, respectively. However, EGM14 showed a significant in-vivo hypoglycaemic effect up to 12 h in rabbits while ELGM14 showed for 9 h. Hence, glipizide microparticles of Eudragit RS 100 (glipizide: polymer 1 : 4) is better suited for oral sustained release formulation.
Madhusudhan
S
S
Department of Pharmacy, Annamalai University, Annamalai Nagar, India.
Panda
Amulya K
AK
Parimalakrishnan
S
S
Manavalan
R
R
Manna
P K
PK
D000180:Acrylic Resins / Q000737:chemistry*; D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D002214:Capsules / Q000737:chemistry*; D016503:Drug Delivery Systems; D005913:Glipizide / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D010316:Particle Size; D011108:Polymers / Q000737:chemistry; D011817:Rabbits; D012996:Solutions / Q000737:chemistry; D013499:Surface Properties
D000180:Acrylic Resins; D001786:Blood Glucose; D002214:Capsules; D007004:Hypoglycemic Agents; D011108:Polymers; D012996:Solutions; C050528:Eudragit RS; D005913:Glipizide